Skip to content

Identification of Clinical, Genetic and Immunological Factors Involved in the Development of Severe Bacterial Infections in Pediatrics

IBSoFACTo : Identification of Clinical, Genetic and Immunological Factors Involved in the Development of Severe Bacterial Infections in Pediatrics

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07111793
Acronym
IBSoFACTo
Enrollment
1401
Registered
2025-08-08
Start date
2026-03-18
Completion date
2029-06-01
Last updated
2026-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Bacterial Infections

Keywords

Severe bacterial infections, Whole-exome sequencing, Inborn errors of immunity, pediatrics

Brief summary

Severe bacterial infections (SBI) are responsible for significant morbidity and mortality in the paediatric population. There is considerable individual variability in children's susceptibility to developing SBIs. This variability is multifactorial, and the mechanisms at work are not yet fully understood. The investigators of this study therefore propose to study a population of children who had particularly severe bacterial infections requiring hospitalization in a pediatric intensive care unit in France between 2015 and 2018. This study is part of a global approach to understanding the mechanisms favoring the occurrence of IBS in pediatrics. The study will initially focus on analyzing the clinical phenotype of these children in terms of the type of infection presented, as well as immunologically with an immune workup of all these patients. The investigators also plan to contact each family individually to identify other episodes of personal or family IBS or other elements suggestive of immune deficiency (opportunistic infections, autoimmune manifestations, severe atopy). The investigators will also assess the persistent sequelae since their infectious episode, and their quality of life following this IBS. In parallel, the genetic analysis of these patients and their parents will be carried out using whole-exome sequencing. The investigators will compare the results with those obtained in 2 IBS-free control populations (N=70 and N=116). The goal is to identify genetic variants that favor the occurrence of IBS in general, and some that are specific to certain bacteria or clinical presentations.

Interventions

OTHERExtended phenotyping

Extended phenotyping (analysis performed at Nantes University Hospital, MANDATORY DELIVERY WITHIN 24 HOURS) = 1 EDTA 3 mL tube for patients included in Nantes.

OTHERBlood sample for WES

Blood sample for WES : 1 x 3 mL EDTA tube (if not included in DIABACT IV biocollection)

OTHERBlood sample for PBMC freezing

Blood sample for PBMC freezing integrated into the biocollection: 1 EDTA tube = 3 mL

OTHERPOPC score evaluation

Assessment of POPC score (Pediatric Overall Performance Category)

Questionnaires completed by parents or children: * SDQ * PedSQL4.0

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

For patients: * Patient included in the DIABACT IV study between 2015 and 2018, following hospitalization in a pediatric intensive care unit in France for a severe bacterial infection. * Patient affiliated to a social security system * Patient alive at the time of inclusion. * Written consent from legal representatives for participation in research. If one of the legal representatives is unable to complete/sign the written consent, it will be sought orally by telephone and recorded in the patient's file. If the patient is over 18, written consent will be obtained. If the patient is a minor, consent will be sought with communication adapted to his/her level of understanding and age. For parents: * Patient's biological parents * Written consent

Exclusion criteria

* Persons under court protection * Refusal to participate in research

Design outcomes

Primary

MeasureTime frameDescription
Identification of innate errors of immunity involved in the development of IBS in pediatrics.At the enrollmentList of rare genetic variants significantly more frequently found in cases than in controls and/or absent in healthy parents.

Secondary

MeasureTime frameDescription
Identification of inborn errors of immunity involved in the development of IBS and their association with abnormalities of the immune balance,At the enrollment
Identification of rare genetic variants favoring certain clinical types of infection, or certain biological and immunological abnormalities.At the enrollment
Identification of immune deficiencies in patients who have developed a severe bacterial infectionAt the enrollment
Assessment of sequelae with the POPC sequelae score (Pediatric Overall Performance Category) at a distance from the IBS episode.At the enrollmentThe POPC sequelae score is a scale from 1 to 6, with 6 being the worst possible outcome.
Assessment of sequelae at a distance from the IBS episode with the Strengths and Weaknesses Questionnaire (SDQ-Fra).At the enrollmentThe SDQ-Fra score is a scale from 0 to 2, with 2 being the worst possible outcome.
Assessment of quality of life at a distance from the IBS episode.At the enrollmentQuality of life will be assessed in this patient population using the Pediatric Quality of Life InventoryTM (scale from 0 to 4, with 4 corresponding to the worst outcome).

Countries

France

Contacts

CONTACTElise LAUNAY
elise.launay@chu-nantes.fr2 40 08 31 79
CONTACTSponsor Department
bp-prom-regl@chu-nantes.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026